<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02052622</url>
  </required_header>
  <id_info>
    <org_study_id>16045</org_study_id>
    <secondary_id>1403740</secondary_id>
    <secondary_id>2011-005026-21</secondary_id>
    <nct_id>NCT02052622</nct_id>
  </id_info>
  <brief_title>Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101</brief_title>
  <official_title>Long-term, Follow-up Study of Subjects Who Completed Phase 3 Trials ATX-101-10-16 or ATX-101-10-17 (Sodium Deoxycholate Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kythera Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kythera Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the long-term safety and maintenance of efficacy of ATX-101 in reduction of
      submental fat
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the study, patients who completed the randomized, double-blind, placebo-controlled phase 3
      studies ATX-101-10-16 and ATX-101-10-17 and where recruited at German study sites are
      followed-up for up to 2 years. No study medication is administered in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score on Clinician-reported submental fat rating scale (1-grade response)</measure>
    <time_frame>24 months</time_frame>
    <description>Maintenance of the treatment effect</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Score on Subject satisfaction rating scale</measure>
    <time_frame>24 months</time_frame>
    <description>Maintenance of the treatment effect</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score on Clinician-reported submental fat rating scale (2-grade response)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on Patient-reported submental fat impact scale (1-grade response)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on Composite submental fat rating scale (1-grade response)</measure>
    <time_frame>24 months</time_frame>
    <description>Improvement observed both in clinician-reported submental fat rating scale and patient-reported submental fat rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with treatment-emergent adverse events</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with treatment-emergent adverse events associated with the treatment area (drug related)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with treatment-emergent adverse events of special interest</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Subcutaneous Fat</condition>
  <arm_group>
    <arm_group_label>ATX-101 [5mg/ml]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects treated with ATX-101 5 mg/mL in previous studies ATX-101-10-16 and ATX-101-10-17, respectively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATX-101 [10mg/ml]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects treated with ATX-101 10 mg/mL in previous studies ATX-101-10-16 and ATX-101-10-17, respectively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects treated with placebo in previous studies ATX-101-10-16 and ATX-101-10-17, respectively</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Examinations and surveys</intervention_name>
    <description>Clinical evaluation, measurement of fat deposit beneath the chin by skinfold caliper, patient-reported outcome questionnaires, photographs, recording of adverse events</description>
    <arm_group_label>ATX-101 [5mg/ml]</arm_group_label>
    <arm_group_label>ATX-101 [10mg/ml]</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent before any study-related activities are carried out

          -  Any subject who successfully completed the final visit (visit 7) of a phase 3 clinical
             trial, ATX-101-10-16 or ATX-101-10-17 for the reduction of submental fat, i.e.
             subjects must have at least one study treatment administered and have completed the
             predecessor study up to visit 7

          -  Willingness to comply with the schedule and procedures of the study

        Exclusion Criteria:

          -  Subjects who, since the completion of the prior phase 3 study ATX-101-10-16 or
             ATX-101-10-17, have had or who are undergoing treatment that may affect the evaluation
             of the submental area (e.g. - but not limited to - long-term treatment with systemic
             corticosteroids, liposuction, surgery or other lipolytic treatment in the submental
             area, treatment with radio frequency, laser procedures, chemical peels, dermal fillers
             in the neck or chin area or botulinum toxin injections in the neck or chin area)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Starnberg</city>
        <state>Bayern</state>
        <zip>82319</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mahlow</city>
        <state>Berlin</state>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Potsdam</city>
        <state>Brandenburg</state>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darmstadt</city>
        <state>Hessen</state>
        <zip>64276</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northeim</city>
        <state>Niedersachsen</state>
        <zip>37154</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Recklinghausen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuppertal</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42287</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ludwigshafen</city>
        <state>Rheinland-Pfalz</state>
        <zip>67061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2014</study_first_submitted>
  <study_first_submitted_qc>January 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2014</study_first_posted>
  <last_update_submitted>June 6, 2014</last_update_submitted>
  <last_update_submitted_qc>June 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>submental fat reduction</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

